Atrium Therapeutics Inc.
RNA evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RNA—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RNA
Atrium Therapeutics Inc. is a biopharmaceutical company pioneering targeted RNA therapeutics for cardiomyopathies, with its lead candidate ATR 1072 entering Phase 1/2 trials for PRKAG2 syndrome.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 1 clinical trial · 1 catalyst for Atrium Therapeutics Inc..
Atrium Therapeutics Inc. is a biopharmaceutical company pioneering targeted RNA therapeutics for cardiomyopathies, with its lead candidate ATR 1072 entering Phase 1/2 trials for PRKAG2 syndrome.
- Atrium Therapeutics is a biopharmaceutical company pioneering the delivery of RNA therapeutics to the heart to transform the standard of care for people living with cardiomyopathies [sec_mda · as of 2026-08-13].
- The company's proprietary technology combines the tissue selectivity of mAbs and other targeted delivery ligands with the precision of oligonucleotides [sec_mda · as of 2026-08-13].
- Lead candidate ATR 1072 has received FDA clearance of its IND application to begin a Phase 1/2 clinical trial for PRKAG2 syndrome [sec · filed 2026-07-14].
- As of June 30, 2026, the company held cash, cash equivalents, and short-term investments of $263.9 million [sec_mda · as of 2026-08-13].
- The company expects its cash to fund operations for at least 12 months from the date of its Quarterly Report filing [sec_mda · as of 2026-08-13].
What works
- Proprietary RNA delivery platform that combines tissue selectivity of mAbs with oligonucleotide precision, enabling targeting of previously undruggable genetic drivers of disease [sec_mda · as of 2026-08-13].
- Lead candidate ATR 1072 has shown preclinical efficacy in improving diastolic function and restoring electrical conduction parameters in PRKAG2 mouse models [sec_mda · as of 2026-08-13].
- ATR 1072 was well tolerated in non-human primate studies with no adverse ECG or heart morphology findings [sec_mda · as of 2026-08-13].
- Second candidate ATR 1086 demonstrated 100% survival and improved cardiac function in a mouse model of PLN mutation [sec_mda · as of 2026-05-14].
What to weigh
- The company has no approved products and does not expect to generate revenue from product sales until candidates advance through clinical development and receive regulatory approval, if ever [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company reported a net loss of $20.2 million and negative shareholders' equity of $61.1 million [sec].
- The company is subject to all risks typical of drug development, including potential unforeseen expenses, difficulties, complications, and delays [sec_mda · as of 2026-05-14].
- Future funding requirements are uncertain and depend on factors such as scope, progress, results, and costs of research and development [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
FDA clearance of IND for ATR 1072 Phase 1/2 trial
“On July 14, 2026, Atrium Therapeutics, Inc. (the "Company") announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug ("IND") application allowing the Company to move forward with its CorventisTM Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 ("PRKAG2") syndrome.”
SEC filings · July 14, 2026
Cash position as of June 30, 2026
“As of June 30, 2026, following the establishment of our independent cash management structure in connection with the Spin-Off, we held cash, cash equivalents, and short-term investments of $263.9 million.”
SEC MD&A · August 13, 2026
Preclinical efficacy of ATR 1072 in mouse models
“Treatment with mATR 1072 improved diastolic function and restored electrical conduction parameters, which we believe establishes a link between PRKAG2 molecular target engagement and functional cardiac benefit.”
SEC MD&A · August 13, 2026
Preclinical efficacy of ATR 1086 in PLN mutation model
“mATR 1086 treatment in this model resulted in 100% survival through the duration of the study for at least 20 weeks. In addition, mATR 1086 treated mice had substantial improvement in cardiac function marked by increased ejection fraction compared to untreated mice.”
SEC MD&A · May 14, 2026
Catalyst timeline
- 2026-10-01 · Phase 2 Start: A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics — The company is expected to initiate a Phase 1/2 clinical trial for ATR 1072 in PRKAG2 syndrome following FDA IND clearance.
Risks & what to watch (4)›
Key risks
- No approved products — The company has no approved products and may never generate revenue from product sales [sec_mda · as of 2026-08-13].
- Negative shareholders' equity — As of June 30, 2026, shareholders' equity was -$61.1 million, indicating accumulated deficits [sec].
- Clinical development risks — The company faces typical drug development risks including potential delays, failures, and unforeseen expenses [sec_mda · as of 2026-05-14].
- Uncertain future funding — Future capital requirements depend on many factors and may increase significantly [sec_mda · as of 2026-08-13].
What to watch
- Initiation and enrollment of the Phase 1/2 Corventis trial for ATR 1072 in PRKAG2 syndrome [sec · filed 2026-07-14].
- Preclinical and clinical progress of second candidate ATR 1086 for PLN mutation [sec_mda · as of 2026-05-14].
- Cash burn rate and any future financing needs given negative equity and net losses [sec].
- Potential partnership or collaboration updates, including the BMS collaboration [sec_mda · as of 2026-05-14].
Sources: News · SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Atrium Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Atrium Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
197.1 months
D/E 0.31 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~32d
No insider transactions in the last 180 days
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
156
Total value held
$179.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,253,738 | $16.8M |
| blackrock, inc. | 1,205,291 | $16.1M |
| susquehanna international group, llp | 1,030,143 | $13.8M |
| ra capital management, l.p. | 864,102 | $11.6M |
| pentwater capital management lp | 602,649 | $8.1M |
| goldman sachs group inc | 349,950 | $4.7M |
| farallon capital management llc | 349,360 | $4.7M |
| vanguard portfolio management llc | 344,369 | $4.6M |
| geode capital management, llc | 319,831 | $4.3M |
| 683 capital management, llc | 300,000 | $4.0M |
Showing top 10 of 156 institutional holders of Atrium Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Mar 2, 2026- % of float
- 6.6%
- Days to cover
- 5.1
- Shares short
- 10,156,722
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RNA short interestFrequently asked questions
What is the AI investment thesis for Atrium Therapeutics Inc.?
Atrium Therapeutics Inc. is a biopharmaceutical company pioneering targeted RNA therapeutics for cardiomyopathies, with its lead candidate ATR 1072 entering Phase 1/2 trials for PRKAG2 syndrome.
What is Atrium Therapeutics Inc.'s next catalyst?
Atrium Therapeutics Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 1/2, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, " — expected October 1, 2026.
Who is the CEO of Atrium Therapeutics Inc.?
Ms. Kathleen P. Gallagher is the chief executive officer of Atrium Therapeutics Inc. (RNA).
Where is Atrium Therapeutics Inc. headquartered?
Atrium Therapeutics Inc. (RNA) is headquartered in San Diego, CA, United States.
What therapeutic areas does Atrium Therapeutics Inc. focus on?
Atrium Therapeutics Inc. develops therapies across Neurology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.